<i>In Vivo</i>Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models
SCL-1 has great potential as an oral immunotherapy that targets immune checkpoint molecules in cancer treatment.
Authors
- Ken D Yamaguchi (ORCID: https://orcid.org/0000-0002-7669-1405)
- Kenichi Urakami (ORCID: https://orcid.org/0000-0002-4751-0978)
- Kouji Maruyama (ORCID: https://orcid.org/0000-0003-3188-4630)
- Chie Maeda
- Akira Iizuka (ORCID: https://orcid.org/0000-0002-2545-5138)
- Tadashi Ashizawa
- Akari Kanematsu
- Takeshi Nagashima (ORCID: https://orcid.org/0000-0002-7261-9908)
- Yasufumi Kikuchi (ORCID: https://orcid.org/0009-0000-3447-8342)
- Takayuki Ando (ORCID: https://orcid.org/0000-0001-8219-976X)
- Yasuto Akiyama (ORCID: https://orcid.org/0000-0003-3813-7726)
- Tomoatsu Ikeya
- Haruo Miyata
- Kazue Yamashita
Institutions
- Shizuoka Cancer Center (JP)
- SRL (Japan) (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2024-12-31
- DOI
- https://doi.org/10.21873/invivo.13805
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28